Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
2.
Pediatr Res ; 81(4): 622-631, 2017 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-28002391

RESUMO

BACKGROUND: Prebiotics and probiotics exert beneficial effects by modulating gut microbiota and immune system. This study evaluates efficacy and safety of an infant formula containing bovine milk-derived oligosaccharides and Bifidobacterium animalis ssp lactis (B. lactis) (CNCM I-3446) on incidence of diarrhea and febrile infections during the first year of life (primary outcome). METHODS: Full-term infants receiving Test or Control (without bovine milk-derived oligosaccharide and B. lactis) formulae were enrolled in a multicenter, randomized, controlled, and double-blind trial with a reference breastfeeding group. . RESULTS: 413 infants were assigned between Test (n = 206) and Control (n = 207) formula. There was no significant difference for diarrhea and febrile infections incidence between groups at 6 (odds ratio (95% confidence interval) = 0.56 (0.26-1.15), P = 0.096) and 12 mo (odds ratio = 0.66 (0.38-1.14), P = 0.119). Test formula was well tolerated, anthropometrics parameters were not significantly different between groups and aligned with WHO growth standards up to 12 mo. Data from test group showed that gut microbiota pattern, fecal IgA and stool pH were brought to be closer to those of breastfed infants. CONCLUSION: An infant formula enriched with bovine milk-derived oligosaccharide and B. lactis supports normal infant growth, is well tolerated and improves intestinal health markers. No differences in diarrhea and febrile infection incidence were found in the population studied.


Assuntos
Fórmulas Infantis/química , Intestinos/fisiologia , Prebióticos , Probióticos/uso terapêutico , Animais , Bifidobacterium animalis , Aleitamento Materno , Bovinos , Diarreia/microbiologia , Método Duplo-Cego , Febre , Microbioma Gastrointestinal , Humanos , Concentração de Íons de Hidrogênio , Sistema Imunitário , Recém-Nascido , Estimativa de Kaplan-Meier , Leite/química , Leite Humano/química , Razão de Chances , Oligossacarídeos/química , Resultado do Tratamento
3.
J Pediatr Gastroenterol Nutr ; 52(6): 756-62, 2011 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-21593648

RESUMO

OBJECTIVES: Breast-feeding induces a gut microbiota rich in bifidobacteria, whereas formula-fed babies have a more diverse colonization. This ecosystem contributes to the development of the immune response and the lower incidence of diarrhea and allergy in breast-fed infants. This randomized double-blind controlled trial aimed to evaluate the bifidogenic effect of a mainly whey protein study formula low in phosphate and protein, allowing a composition closer to that of human milk. PATIENTS AND METHODS: One hundred ninety healthy infants exclusively received study formula with or without Bifidobacterium longum (BL999), or a control formula for up to 4 months. Breast-fed infants served as a reference population. Stool samples collected at 2 months of age were analyzed for bacterial counts (log colony-forming unit [CFU]/g). RESULTS: Bifidobacteria counts were significantly higher in infants receiving the study formula alone (10.0[0.8], P < 0.0001, median [interquartile range]) or with BL999 (9.8[1.4], P < 0.01) than control (9.2[3.5]), and were similar to breast-fed infants (10.1[0.4], P > 0.05). The difference between the 2 study groups was 0.16 log CFU/g (90% confidence interval [CI] [0-0.4]), within the predefined equivalence margin. Microbiota profile, as a percentage of total bacteria counts, showed about 50% Bifidobacteria, 8% Enterobacteria, and <10% Clostridia in study formulae and breast-fed infants versus 22%, 13%, and 19% in controls, respectively. There were no significant differences in growth measurements, digestive tolerance, and adverse events between groups. CONCLUSIONS: This study showed that infant formula closer resembling human milk was more bifidogenic than the control formula and led to a microbiota profile similar to that for breast-fed infants.


Assuntos
Bifidobacterium , Microbiologia de Alimentos , Trato Gastrointestinal/microbiologia , Fórmulas Infantis , Recém-Nascido , Metagenoma , Probióticos , Carga Bacteriana , Aleitamento Materno , Clostridium/isolamento & purificação , Método Duplo-Cego , Enterobacteriaceae/isolamento & purificação , Fezes/microbiologia , Feminino , Humanos , Masculino , Leite Humano/microbiologia
4.
Ann Nutr Metab ; 55(4): 334-40, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19844090

RESUMO

BACKGROUND/AIMS: Breast milk is the best source of nutrition for the growth of the newborn infant. It is therefore essential that mothers who cannot breastfeed or choose not to are provided with alternatives that closely match the composition and functionality of breast milk. This study aimed to investigate the growth effects of probiotic-supplemented formulas on both healthy and vulnerable populations of infants. METHODS: A meta-analysis of data from 5 randomized controlled clinical trials that included infants fed formulas containing a probiotic Bifidobacterium lactis CNCM I-3446 was performed (n = 525). A sub-analysis was performed among infants of HIV-positive mothers (n = 120). Growth measurements (gain in weight and body mass index, BMI, from enrollment to 120 days) were compared between infants fed a formula containing B. lactis and those fed a control formula. Changes in length and Z-scores were also compared. RESULTS: Formula with B.lactis was demonstrated to be at least as good as formula without B. lactis in the meta-analysis of 5 studies. The lower boundary of the 95% confidence interval (CI) of the differences in mean weight gain (95% CI 0.09-2.93 g/day) was above the predefined non-inferiority margin of -3.0 g/day. Moreover, among infants with HIV-positive mothers, weight gain of those taking B. lactis was significantly higher than of those not taking B. lactis, by 3.1 g/day (95% CI 0.4-5.8 g/day, p = 0.0226) and the BMI gains were significantly higher, by 6.4 g/m(2)/day (95% CI 0.0.3-12.5 g/m(2)/day, p = 0.0400). The corresponding weight for age and BMI Z-scores were also significantly higher, by 0.37 (95% CI 0.03-0.71, p = 0.0308) and by 0.42 (95% CI 0.02-0.83, p = 0.0377), respectively, whereas differences in length gain or length-for-age Z-score were not significant. Among infants in the non-HIV mothers group, there were no significant differences between infants fed formulas with or without B. lactis, for any of the growth parameters. CONCLUSIONS: The analysis suggests that B. lactis may have a positive effect on growth in vulnerable populations, specifically in infants born to mothers with HIV.


Assuntos
Bifidobacterium , Fórmulas Infantis , Probióticos , Aumento de Peso , Antropometria , Feminino , Infecções por HIV , Humanos , Lactente , Recém-Nascido , Masculino , Mães , Ensaios Clínicos Controlados Aleatórios como Assunto
5.
Asia Pac J Clin Nutr ; 19(4): 473-80, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-21147707

RESUMO

Development of new infant formulas aims to replicate the benefits of breast milk. One benefit of breast milk over infant formulas is greater gastrointestinal comfort. We compared indicators of gastrointestinal comfort in infants fed a whey-predominant formula containing long-chain polyunsaturated fatty acids, galacto-oligo-saccharides and fructo-oligosaccharides, and infants fed a control casein-predominant formula without additional ingredients. The single-centre, prospective, double-blind, controlled trial randomly assigned healthy, full-term infants (n=144) to receive exclusively either experimental or control formula from 30 days to 4 months of age. A group of exclusively breast-fed infants served as reference (n=80). At 1, 2, 3, and 4 months, infants' growth parameters were measured and their health assessed. Parents recorded frequency and physical characteristics of infants' stool, frequency of regurgitation, vomiting, crying and colic. At 2-months, gastric emptying (ultrasound) and intestinal transit time (H2 breath test) were measured, and stool samples collected for bacterial analysis. Compared to the control (n=69), fewer of the experimental group (n=67) had hard stools (0.7 vs 7.5%, p<0.001) and more had soft stools (90.8 vs 82.3%, p<0.05). Also compared to the control, the experimental group's stool microbiota composition (mean % bifidobacteria: 78.1 (experimental, n=17), 63.7 (control, n=16), 74.3 (breast-fed, n=20), gastric transit times (59.6 (experimental, n=53), 61.4 (control, n=62), 55.9 (breast-fed, n=67) minutes) and intestinal transit times (data not shown) were closer to that of the breast-fed group. Growth parameter values were similar for all groups. The data suggest that, in infants, the prebiotic-containing whey-based formula provides superior gastrointestinal comfort than a control formula.


Assuntos
Ácidos Graxos Insaturados/administração & dosagem , Gastroenteropatias/prevenção & controle , Fórmulas Infantis/métodos , Proteínas do Leite/uso terapêutico , Oligossacarídeos/administração & dosagem , Prebióticos , Análise de Variância , Aleitamento Materno , Caseínas/administração & dosagem , Desenvolvimento Infantil/efeitos dos fármacos , Cólica/prevenção & controle , Choro , Método Duplo-Cego , Fezes/microbiologia , Feminino , Seguimentos , Esvaziamento Gástrico/efeitos dos fármacos , Trânsito Gastrointestinal/efeitos dos fármacos , Humanos , Lactente , Recém-Nascido , Refluxo Laringofaríngeo/prevenção & controle , Masculino , Estudos Prospectivos , Vômito/prevenção & controle , Proteínas do Soro do Leite
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA